๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results

โœ Scribed by Elisabeth I. Heath; George R. Blumenschein; Roger B. Cohen; Patricia M. LoRusso; Noelle K. LoConte; Sindy T. Kim; Ana Ruiz-Garcia; Richard C. Chao; George Wilding

Publisher
Springer
Year
2010
Tongue
English
Weight
210 KB
Volume
68
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase I clinical trial of weekly combine
Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors
โœ Jacob Lokich ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 70 KB ๐Ÿ‘ 2 views

A Phase I and feasibility study of combined docetaxel (D) plus paclitaxel (P) was undertaken to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for each analogue delivered concomitantly on a weekly schedule. ## METHODS. Patients were accrued in 3-6 patient cohorts to P

Randomized trial of carboplatin plus ami
Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors
โœ G. Thomas Budd; Ram Ganapathi; David J. Adelstein; Robert Pelley; Thomas Olencki ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 91 KB ๐Ÿ‘ 2 views

## Background: To test the hypothesis that the cytoprotectant amifostine attenuates the thrombocytopenia produced by carboplatin, the authors performed a randomized trial comparing treatment with carboplatin alone versus the combination of amifostine and carboplatin. ## Methods: Patients with ref